Core Insights - INmune Bio Inc. reported its financial results for Q3 2025, highlighting advancements in its clinical programs and a significant reduction in net loss compared to the previous year [1][10]. Financial Performance - The net loss attributable to common stockholders for Q3 2025 was approximately $6.5 million, a decrease from approximately $12.1 million in Q3 2024 [10]. - Research and development expenses totaled approximately $4.9 million for Q3 2025, down from approximately $10.1 million in Q3 2024 [10]. - General and administrative expenses were approximately $2.5 million for Q3 2025, compared to approximately $2.2 million in Q3 2024 [10]. - As of September 30, 2025, the company had cash and cash equivalents of approximately $27.7 million [10]. Product Development Highlights - The CORDStrom™ platform successfully completed its first two commercial pilot-scale manufacturing runs, with plans to file a Marketing Authorization Application (MAA) in mid-2026 for recessive dystrophic epidermolysis bullosa (RDEB) [5]. - XPro™, a selective soluble TNF neutralizer, showed promising results in a Phase 2 trial for early Alzheimer's disease, demonstrating cognitive benefits and a favorable safety profile [5][11]. - The INKmune® platform is currently in a Phase I/II trial for metastatic castration-resistant prostate cancer, with data expected to be released in Q4 2025 [12][10]. Corporate Updates - Dr. RJ Tesi retired, and David Moss was appointed as the new President & CEO [10]. - Cory Ellspermann was appointed as CFO, and Kelly Ganjei was named Chairman of the board of directors [10]. - The company plans to present additional data on CORDStrom™ and imaging data from the Phase 2 MINDFuL trial in Q4 2025 [10].

Core Insights - INmune Bio Inc. has successfully completed its Phase I/II trial of INKmune™ for men with metastatic castration-resistant prostate cancer (mCRPC), meeting both primary and secondary endpoints, and is now closed to further enrollment [1][2] - INKmune™ demonstrated an excellent safety profile across all three dose levels, with significant improvements in NK cell activation biomarkers observed in patients with low NK cell activation [2][3] - The company plans to advance the INKmune™ program by designing a randomized Phase 2b trial targeting patients with less severe disease to better measure the drug's effects and potential clinical benefits [3] Product Overview - INKmune™ is a pharmaceutical-grade, replication-incompetent human tumor cell line that primes resting NK cells to become tumor-killing memory-like NK cells, with effects persisting for over 100 days [4] - The treatment is patient-friendly, requiring no pre-medication or additional cytokine therapy, and can be administered via simple intravenous infusion as an outpatient procedure [5] - INKmune™ is tumor agnostic, applicable to various NK-resistant tumors, including leukemia, lymphoma, myeloma, and several solid tumors [5] Company Background - INmune Bio Inc. is a publicly traded clinical-stage biotechnology company focused on developing treatments that target the innate immune system to combat diseases [6] - The company has three product platforms: DN-TNF for chronic inflammation and cognitive disorders, Natural Killer Cell Priming Platform including INKmune™, and CORDStrom™ for regenerative medicine [6]